Exhibit 99.1



ELECTRO-OPTICAL SCIENCES, INC. SIGNS PRODUCTION AGREEMENT WITH ASKION GMBH TO
PRODUCE MELAFIND(R) IMAGING DEVICE

IRVINGTON, N.Y., Jan 30, 2006 /PRNewswire-FirstCall via COMTEX News Network/ --
Electro-Optical Sciences, Inc. (EOS) (Nasdaq: MELA), a medical device company
focused on designing and developing a non-invasive, point-of-care instrument to
assist in the early diagnosis of melanoma, today announced that it has entered
into an agreement with ASKION GmbH for the production of the MelaFind(R)
hand-held imaging device.

The agreement calls for ASKION to produce MelaFind imaging devices for EOS to be
utilized in the company's pivotal trial. EOS anticipates conducting the trial at
over 20 clinical study sites in the U.S. The purpose of the pivotal trial is to
establish the safety and efficacy of MelaFind in the imaging of suspicious skin
lesions. Financial terms of the agreement were not disclosed.

"This agreement is an important milestone for EOS and is a significant step in
our pre-commercialization process," said Joseph V. Gulfo, President and CEO of
EOS. "2006 will be an exciting year for EOS as we conduct our clinical trials
and anticipate PMA approval and commercialization of MelaFind in 2007."

"ASKION has a solid reputation for top quality production and manufacturing. I
have had first-hand dealings with ASKION management and personnel for 15 years
since my days at Bayer Diagnostics US and AGFA. We look forward to working with
them to produce these commercial grade units," said Gerald Wagner, PhD, Acting
Chief Operating Officer and member of EOS's Board of Directors.

"We are pleased that EOS has selected ASKION to produce the MelaFind imaging
system. We look forward to supporting the company in their strategy of
developing a leading technology in the detection of melanoma," said Lutz Doms,
Managing Director of ASKION GmbH.

About Electro-Optical Sciences, Inc.

EOS is a medical device company focused on designing and developing a
non-invasive, point-of-care instrument to assist in the early diagnosis of
melanoma. MelaFind, EOS's flagship product, features a hand-held imaging device
that emits multiple wavelengths of light to capture images of suspicious
pigmented skin lesions and extract data. The data are then analyzed against
EOS's proprietary database of melanomas and benign lesions using sophisticated
algorithms in order to provide information to the physician and produce a
recommendation of whether the lesion should be biopsied.

Melanoma is the deadliest of skin cancers, responsible for approximately 80% of
all skin cancer deaths. Unless melanoma is detected early and excised with
proper margins, the patient survival rate is poor, as there is currently no cure
for advanced stage melanoma.

For more information on EOS, visit http://www.eosciences.com.

About ASKION GmbH

The company started as a part of Agfa-Gevaert AG in 1991, mostly with employees
from the former Carl Zeiss Jena. Its focus originally was on development and
production of printing machines for the photo industry. In 1995 it expanded
these activities to digital printing devices using color laser exposure systems.

ASKION GmbH was formed in 2005 as a management buy-out. Located in the center of
the Jena-Dresden-Leipzig industrial and technology region, the company's
facilities include 77,000 square ft R&D and manufacturing areas, which have
cleanrooms, and climate- and light-testing equipment. ASKION draws upon many
years of experience in the development of complex systems, including electronic
hard- and software, opto-electronics and test equipment as well as strict
adherence to quality management standards. Production capabilities encompass:
samples, prototypes, initial ramp-up and commercial production or transfer of
serial production to other locations. Specific applications include printing and
exposure as well as medical devices and instrumentation. For more information on
ASKION visit http://www.Askion.com

Safe Harbor

This press release includes "forward-looking statements" within the meaning of
the Securities Litigation Reform Act of 1995. These statements include but are
not limited to our plans, objectives, expectations and intentions and other
statements that contain words such as "expects," "contemplates," "anticipates,"
"plans," "intends," "believes" and variations of such words or similar
expressions that predict or indicate future events or trends, or that do not
relate to historical matters. These statements are based on our current beliefs
or expectations and are inherently subject to significant uncertainties and
changes in circumstances, many of which are beyond our control. There can be no
assurance that our beliefs or expectations will be achieved. Actual results may
differ materially from our beliefs or expectations due to economic, business,
competitive, market and regulatory factors.

SOURCE Electro-Optical Sciences, Inc.

Fern Lazar of Lazar Partners for Electro-Optical Sciences, Inc.,
+1-212-867-1762, flazar@lazarpartners.com